摘要
背景:为什么全球范围内引起急性神经肌肉麻痹的主要原因是自身免疫性疾病,而目前还没有一种特征明确的病因或有效的治疗方法?Guillain-Barre综合征(GBS)存在不同的临床变异,加上大量病原体可能导致感染,有时但并非总是先于该综合征的发展,给预后和治疗带来很大程度的不确定性。在后基因组时代,用于生物分子高通量分析的组学技术的发展使生物系统的描述达到了前所未有的深度。在此背景下,本文综述了后基因组学技术在GBS研究中的应用.方法:对文献数据库进行结构化检索,总结后基因组学技术在GBS研究中的应用现状。检索到的论文的质量使用标准工具进行了评估,其中34篇被包括在审查中。迄今为止,转录组学和蛋白质组学已经成为GBS研究中独特的后基因组学方法.这些研究大多是在脑脊液标本上进行的,而对其他样本如血清、雪旺细胞和人周围神经的研究则很少。结果与结论:在后基因组学时代,转录组学和蛋白质组学技术为更好地理解GBS的免疫学和病理机制以及识别潜在的生物标记物提供了可能,但这些结果仅显示出冰山一角,而后基因组学方法为GBS的研究提供了很大的潜力。通过系统生物学方法整合不同的组学数据集,可以使基于网络的分析能够描述疾病过程中所涉及的分子机制的复杂性和功能性,从而有助于发现新的生物标志物,这些标志物可用于改进诊断,预测疾病进展,提高我们对病理的理解,并作为GBS的治疗靶点。
关键词: 后基因组学方法,格林 - 巴利综合征,转录组学,蛋白质组学,系统生物学,神经退行性疾病。
Current Medicinal Chemistry
Title:The Impact of Post-Genomics Approaches in Neurodegenerative Demyelinating Diseases: The Case of Guillain-Barré Syndrome
Volume: 25 Issue: 29
关键词: 后基因组学方法,格林 - 巴利综合征,转录组学,蛋白质组学,系统生物学,神经退行性疾病。
摘要: Background: Why an autoimmune disease that is the main cause of the acute neuromuscular paralysis worldwide does not have a well-characterized cause or an effective treatment yet? The existence of different clinical variants for the Guillain-Barré syndrome (GBS) coupled with the fact that a high number of pathogens can cause an infection that sometimes, but not always, precedes the development of the syndrome, confers a high degree of uncertainty for both prognosis and treatment. In the post-genomic era, the development of omics technologies for the high-throughput analysis of biological molecules is allowing the characterization of biological systems in a degree of depth unimaginable before. In this context, this work summarizes the application of post-genomics technologies to the study of GBS.
Methods: We performed a structured search of bibliographic databases for peer-reviewed research literature to outline the state of the art with regard the application of post-genomics technologies to the study of GBS. The quality of retrieved papers was assessed using standard tools and thirty-four were included in the review. To date, transcriptomics and proteomics have been the unique post-genomics approaches applied to GBS study. Most of these studies have been performed on cerebrospinal fluid samples and only a few studies have been conducted with other samples such as serum, Schwann cells and human peripheral nerve.
Results and Conclusion: In the post-genomics era, transcriptomics and proteomics have shown the possibilities that omics technologies can offer for a better understanding of the immunological and pathological mechanisms involved in GBS and the identification of potential biomarkers, but these results have only shown the tip of the iceberg and there is still a long way to exploit the full potential that post-genomics approaches could offer to the study of the GBS. The integration of different omics datasets through a systems biology approach could allow network-based analyses to describe the complexity and functionality of the molecular mechanisms involved in the course of disease facilitating the discovery of novel biomarkers that could be used to improve the diagnosis, predict the disease progression, improve our understanding of the pathology, and serve as therapeutic targets for GBS.
Export Options
About this article
Cite this article as:
The Impact of Post-Genomics Approaches in Neurodegenerative Demyelinating Diseases: The Case of Guillain-Barré Syndrome, Current Medicinal Chemistry 2018; 25 (29) . https://dx.doi.org/10.2174/0929867325666180314121813
DOI https://dx.doi.org/10.2174/0929867325666180314121813 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of Hepatocyte Apoptosis: Cross-talk Between Bile Acids and Nuclear Steroid Receptors
Current Medicinal Chemistry T-Lymphocytes: A Target for Stimulatory and Inhibitory Effects of Zinc Ions
Endocrine, Metabolic & Immune Disorders - Drug Targets No Zinc Deficiency But a Putative Immunosuppressive Role for Labile Zn in Patients with Systemic Autoimmune Disease
Current Rheumatology Reviews Dendritic Cells in Autoimmune Liver Diseases
Current Immunology Reviews (Discontinued) Methotrexate in the Treatment of Psoriasis and Rheumatoid Arthritis: Mechanistic Insights, Current Issues and Novel Delivery Approaches
Current Pharmaceutical Design The Critical Role of Toll-Like Receptor Signaling Pathways in the Induction and Progression of Autoimmune Diseases
Current Molecular Medicine Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery Altered Peptide Ligand Antagonism: From Immune Evasion to Immunotherapy
Drug Design Reviews - Online (Discontinued) Mesenchymal Stem Cell as a Potential Therapeutic for Inflammatory Bowel Disease- Myth or Reality?
Current Stem Cell Research & Therapy The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy Control of Interleukin-1β Secretion in Inflammation and Immune Response
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design Basement Membrane Peptides: Functional Considerations and Biomedical Applications in Autoimmunity
Current Medicinal Chemistry Diabetes Mellitus: A Potential Target for Stem Cell Therapy
Current Stem Cell Research & Therapy Role of Innate Immunity in Triggering and Tuning of Autoimmune Diabetes
Current Molecular Medicine Oral Agents in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthetic Glycolipid Ligands for Human iNKT Cells as Potential Therapeutic Agents for Immunotherapy
Current Medicinal Chemistry Regulatory T Cell Therapy for Type I Diabetes Targeting on β Cell Associated Autoantigens
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases
Current Topics in Medicinal Chemistry